



Contents

- 475 Hyaluronic acid treatment of facial fat atrophy in HIV-positive patients
H Bugge, A Negaard, L Skeie & B Bergersen
- 483 Incidence of anaemia among HIV-infected patients treated with highly active antiretroviral therapy
SM Curkendall, JT Richardson, MF Emans, AE Fisher & F Everhard
- 491 Hepatitis C is associated with type 2 diabetes mellitus in HIV-infected persons without traditional risk factors
MK Jain, C Aragaki, L Fischbach, S Gibson, R Arora, L May, K Vardhini & WM Lee
- 498 Validation of three-dimensional laser scanning for the assessment of facial fat changes
NI Paton, Y Yang, Y-Y Sitoh & Naing Oo Tha
- 504 Presence of M184I/V in minor HIV-1 populations of patients with lamivudine and/or didanosine treatment failure
V Svedhem, T Bergroth, K Lidman & A Sönnberg
- 511 Impact of transmission of drug-resistant HIV on the course of infection and the treatment success. Data from the German HIV-1 Seroconverter Study
G Poggensee, C Kücherer, J Werning, S Somogyi, B Bieniek, S Dupke, H Jessen & O Hamouda for the HIV-1 Seroconverter Study Group
- 520 Improved cognitive function as a consequence of hepatitis C virus treatment
HH Thein, P Maruff, MD Krahn, JM Kaldor, DJ Koorey, BJ Brew & GJ Dore
- 529 Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors
P Chetchotisakd, S Anunnatsiri, P Mootsikapun, S Kiertiburanakul, T Anekthananon, C Bowonwatanuwong, B Kowadisaiburana, K Supparatpinyo & K Ruxrungtham and the study team
- 536 HIV in the UK 1980–2006: reconstruction using a model of HIV infection and the effect of antiretroviral therapy
AN Phillips, C Sabin, D Pillay & JD Lundgren
- 547 Trends and determinants of severe morbidity in HIV-infected patients: the ANRS CO3 Aquitaine Cohort, 2000–2004
F Bonnet, G Chêne, R Thiébaud, M Dupon, S Lawson-Ayayi, JL Pellegrin, F Dabis & P Morlat for the Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA)
- 555 Peripheral arterial disease in HIV-infected and uninfected women
A Sharma, S Holman, R Pitts, HL Minkoff, JA DeHovitz & J Lazar
- 561 Impact of GB virus type C infection on mother-to-child HIV transmission in the Women and Infants Transmission Study Cohort
E Handelsman, I Cheng, B Thompson, R Hershov, LM Mofenson, FB Hollinger, KT Chen, SK Burchett, D Klinzman & JT Stapleton and the Women and Infants Transmission Study Group (WITS)

- Correspondence 568 Hill A, Moyle G. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials. *HIV Med* 2007; 8: 259–264
JM Llibre & N Pérez-Alvarez
- 570 Relative antiviral efficacy should not be inferred from cross-trial comparisons
D Hall
- 571 Authors' Reply to Drs JM Llibre, N Pérez-Alvarez & D Hall
A Hill & G Moyle
- 573 Vanishing bile duct syndrome in a patient with advanced AIDS. *HIV Med* 2007; 8: 70–72
T Aldeen & S Davies
- Miscellaneous 575 A note of thanks to referees for Volume 8, 2007